Hampton, UK – 03 December 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. In this new role, Satish will be responsible for leading the development and implementation of the UK and global regulatory strategy for Touchlight.
Satish has over 14 years of global regulatory experience in the pharmaceutical industry, having consulted organisations of all sizes in the pre-approval regulatory phase as well as on post-approval life cycle maintenance of biopharmaceutical products. Prior to joining Touchlight, Satish worked in various regulatory positions at UCB, Johnson and Johnson, and GSK. He has a Master’s degree in Pharmaceutical Sciences and is one of the consultant editors for TOPRA Regulatory Rapporteur.
“We are delighted to have Satish join Touchlight in this exciting period, when nucleic acid vaccines are in the spotlight,” said Jonny Ohlson, Executive Chairman of Touchlight. “Satish is an accomplished regulatory affairs executive with in-depth experience in regulatory affairs in all phases of pharmaceutical research and development, at a global level. We look forward to Satish supporting us in progress approvals for Touchlight’s pipeline.”
Commenting on his appointment, Satish Muchakayala said: “With a Covid-19 nucleic acid vaccine now approved, efficient large scale manufacturing of these vaccines will be crucial. Touchlight’s dbDNA technology has the ability to accelerate manufacturing without compromising on safety or efficacy. Regulatory affairs will now be key, and I am excited to join Touchlight at such an important time for the company’s growth.”
- ENDS -
Notes to Editors
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
Jonny Ohlson, CEO
At Instinctif Partners
Tim Watson / Agnes Stephens / Katie Duffell